局限性前列腺癌的立体定向放射治疗:三项前瞻性试验的10年结局
三项加拿大临床试验纳入2006至2013年低危和中危局限性前列腺癌患者267例,接受5次分割35至40 Gy的立体定向体部放疗(SABR)。中位随访10.3年,10年生化失败率7.7%,总生存率84.1%,前列腺癌特异性生存率99.2%,无转移生存率98.8%;27例(10.1%)发生第二恶性肿瘤,其中6例(22.2%)可能与既往放疗相关。
要点
- SABR治疗低危和中危局限性前列腺癌显示良好的长期疾病控制。
- 10年生化失败率7.7%,前列腺癌特异性生存率99.2%,无转移生存率98.8%。
- 第二恶性肿瘤发生率为10.1%,与人群背景发生率一致。
核心结论
- SABR对低危和中危局限性前列腺癌显示出良好的长期疾病控制。
- 接受前列腺癌治疗的患者发生第二恶性肿瘤的风险为中等,与人群背景发生率一致。
研究设计与样本
- 研究纳入3项加拿大临床试验中2006至2013年入组的低危和中危局限性前列腺癌患者。
- 所有患者接受前列腺SABR,剂量为35至40 Gy分5次,在11至29天内完成。
- 研究共纳入267例患者,中位随访10.3年(四分位距7.8至12.7年)。
主要发现
- 10年生化失败率为7.7%(95%CI 3.9%至11.5%)。
- 10年总生存率为84.1%(95%CI 79.3%至89.1%),前列腺癌特异性生存率为99.2%(95%CI 98.1%至100%),无转移生存率为98.8%(95%CI 97.5%至100%)。
- 267例患者中27例(10.1%)发生第二恶性肿瘤,其中6/27例(22.2%)被分类为可能与既往放疗相关(n=3)或可能相关(n=3)。
- 10年无第二恶性肿瘤生存率为89.2%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: SABR is growingly accepted for the treatment of localized prostate cancer with recent randomized trials showing noninferiority compared with conventional or moderately hypofractionated radiation therapy. The natural history of prostate cancer necessitates extended surveillance for recurrence; however, there are a few prospective studies reporting long-term outcomes. METHODS AND MATERIALS: This study included patients with low- and intermediate-risk localized prostate cancer from 3 Canadian clinical trials enrolled from 2006 to 2013. All patients received SABR to the prostate consisting of 35 to 40 Gy in 5 fractions over 11 to 29 days. Prostate specific antigen, distant metastasis, and vital status were prospectively recorded. The occurrence of a second malignancy after treatment was assessed by a chart review and classified using modified Cahan's criteria. RESULTS: Two hundred sixty-seven patients were included. Median follow-up was 10.3 years (interquartile range, 7.8-12.7). Ten-year biochemical failure (95% confidence interval) was 7.7% (3.9%-11.5%); 10-year overall survival, prostate cancer-specific survival, and freedom from metastasis were 84.1% (79.3%-89.1%), 99.2% (98.1%-100%), and 98.8% (97.5%-100%), respectively. Twenty-seven of 267 (10.1%) patients experienced a second malignancy (SM), with 6/27 patients (22.2%) classified as having a SM likely (n = 3) or possibly (n = 3) related to prior radiation therapy. Ten-year freedom from SM was 89.2%. CONCLUSIONS: SABR shows excellent long-term disease control for low- and intermediate-risk localized prostate cancer. Patients treated for prostate cancer have a moderate risk of SM, consistent with background rates for the population.
引用
- Kennedy TAC, Ong WL, Quon H, et al. Stereotactic Radiation Therapy for Localized Prostate Cancer: 10-Year Outcomes From Three Prospective Trials. Int J Radiat Oncol Biol Phys. 2024. PMID: 39293531. doi:10.1016/j.ijrobp.2024.09.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。